ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $37,619,853 | -12.7% | 350,866 | -0.6% | 3.56% | -29.5% |
| Q4 2022 | $43,088,441 | -16.1% | 352,808 | -29.1% | 5.06% | -26.1% |
| Q3 2022 | $51,356,000 | +27.8% | 497,347 | +15.1% | 6.85% | -14.5% |
| Q2 2022 | $40,175,000 | +6.4% | 432,170 | +34.4% | 8.01% | -19.7% |
| Q1 2022 | $37,745,000 | +28.6% | 321,621 | +47.4% | 9.98% | +19.1% |
| Q4 2021 | $29,349,000 | – | 218,158 | – | 8.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |